Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ARG1 | P05089 | 1/20 | 0.39 |
| ▸ | ARG2 | P78540 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24636213 | 1.00 | ARG1 (0.39) | ARG1ARG2CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL24636215 | 1.00 | ARG1 (0.39) | ARG1ARG2CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL24636252 | 1.00 | ARG1 (0.39) | ARG1ARG2CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL24636214 | 0.77 | — | — | |
| SCHEMBL17469315 | 0.71 | SLC6A2 (0.43) | CYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL23128322 | 0.71 | SLC6A2 (0.43) | CYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL30085352 | 0.67 | ARG1 (0.53) | ARG1ARG2CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL1359692 | 0.67 | ARG1 (0.53) | ARG1ARG2CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL1359695 | 0.67 | ARG1 (0.53) | ARG1ARG2CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL28174553 | 0.67 | ARG1 (0.53) | ARG1ARG2CYP2D6SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220259217-A1 | PROCESSES AND INTERMEDIATES FOR PRODUCING DIAZASPIRO LACTAM COMPOUNDS | INNOVIVA TRC HOLDINGS LLC | 2022-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220259217-A1 | PROCESSES AND INTERMEDIATES FOR PRODUCING DIAZASPIRO LACTAM COMPOUNDS | DDO, DHPS, PGLS | ARG1 2789/4885ARG2 3161/4885CYP2D6 377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.